261 related articles for article (PubMed ID: 21822052)
1. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.
Martínez-Paniagua MA; Baritaki S; Huerta-Yepez S; Ortiz-Navarrete VF; González-Bonilla C; Bonavida B; Vega MI
Cell Cycle; 2011 Aug; 10(16):2792-805. PubMed ID: 21822052
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1.
Huerta-Yepez S; Vega M; Escoto-Chavez SE; Murdock B; Sakai T; Baritaki S; Bonavida B
Nitric Oxide; 2009 Feb; 20(1):39-52. PubMed ID: 18778787
[TBL] [Abstract][Full Text] [Related]
4. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.
Huang S; Okumura K; Sinicrope FA
Clin Cancer Res; 2009 Jan; 15(1):150-9. PubMed ID: 19118042
[TBL] [Abstract][Full Text] [Related]
5. Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs.
Martinez-Paniagua MA; Vega MI; Huerta-Yepez S; Baritaki S; Vega GG; Hariharan K; Bonavida B
Mol Cancer Ther; 2012 Mar; 11(3):572-81. PubMed ID: 22267549
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.
Baritaki S; Huerta-Yepez S; Sakai T; Spandidos DA; Bonavida B
Mol Cancer Ther; 2007 Apr; 6(4):1387-99. PubMed ID: 17431117
[TBL] [Abstract][Full Text] [Related]
7. A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells.
Vega MI; Baritaki S; Huerta-Yepez S; Martinez-Paniagua MA; Bonavida B
Leuk Lymphoma; 2011 Jan; 52(1):108-21. PubMed ID: 21133714
[TBL] [Abstract][Full Text] [Related]
8. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis.
Mott JL; Bronk SF; Mesa RA; Kaufmann SH; Gores GJ
Mol Cancer Ther; 2008 Aug; 7(8):2339-47. PubMed ID: 18723481
[TBL] [Abstract][Full Text] [Related]
9. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation.
Baritaki S; Katsman A; Chatterjee D; Yeung KC; Spandidos DA; Bonavida B
J Immunol; 2007 Oct; 179(8):5441-53. PubMed ID: 17911631
[TBL] [Abstract][Full Text] [Related]
10. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
[TBL] [Abstract][Full Text] [Related]
13. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
[TBL] [Abstract][Full Text] [Related]
14. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
Nguyen M; Marcellus RC; Roulston A; Watson M; Serfass L; Murthy Madiraju SR; Goulet D; Viallet J; Bélec L; Billot X; Acoca S; Purisima E; Wiegmans A; Cluse L; Johnstone RW; Beauparlant P; Shore GC
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19512-7. PubMed ID: 18040043
[TBL] [Abstract][Full Text] [Related]
15. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.
Jiang CC; Wroblewski D; Yang F; Hersey P; Zhang XD
Neoplasia; 2009 Sep; 11(9):945-55. PubMed ID: 19724688
[TBL] [Abstract][Full Text] [Related]
16. Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells.
Sarif Z; Tolksdorf B; Fechner H; Eberle J
Mol Carcinog; 2020 Nov; 59(11):1256-1268. PubMed ID: 32885857
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma.
Hetschko H; Voss V; Horn S; Seifert V; Prehn JH; Kögel D
J Neurooncol; 2008 Feb; 86(3):265-72. PubMed ID: 17924059
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Jane EP; Premkumar DR; Pollack IF
Mol Cancer Ther; 2011 Jan; 10(1):198-208. PubMed ID: 21220502
[TBL] [Abstract][Full Text] [Related]
19. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis.
Baritaki S; Militello L; Malaponte G; Spandidos DA; Salcedo M; Bonavida B
Int J Oncol; 2011 Jun; 38(6):1683-94. PubMed ID: 21455568
[TBL] [Abstract][Full Text] [Related]
20. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
